Get the Stockscreener App
154.87
1.29%
-2.02
Pre-market:
158.84
3.97
+2.56%
Insulet Corp stock is traded at $154.87, with a volume of 949.13K.
It is down -1.29% in the last 24 hours and down -20.01% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$156.89
Open:
$154.55
24h Volume:
949.13K
Relative Volume:
0.79
Market Cap:
$10.73B
Revenue:
$2.90B
Net Income/Loss:
$302.80M
P/E Ratio:
36.05
EPS:
4.2965
Net Cash Flow:
$387.80M
1W Performance:
+5.03%
1M Performance:
-20.01%
6M Performance:
-53.24%
1Y Performance:
-51.75%
1-Day Range:
$152.28
$155.90
1-Week Range:
$145.73
$158.32
52-Week Range:
$145.59
$354.88
Insulet Corp Stock (PODD) Company Profile
Name
Insulet Corp
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
154.87 | 10.87B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corp Stock (PODD) Latest News
11 Best Medical Technology Stocks to Buy Right Now - Insider Monkey
Are Wall Street Analysts Bullish on Insulet Stock? - Barchart.com
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Here’s Insiders Fund’s Thesis on Insulet Corporation (PODD) - Insider Monkey
PODD News | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet Corporation (PODD) Announces Amendments to Bylaws and An - GuruFocus
Insulet Corp (PODD) director granted 1,660 RSUs vesting in 2027 - Stock Titan
Insulet (PODD) director receives 1,660 RSU equity award vesting in 2027 - Stock Titan
Insulet (PODD) director Timothy Scannell receives 1,660-share RSU equity award - Stock Titan
Insulet (PODD) director Minogue receives 1,660 RSUs and reports trust-held shares - Stock Titan
Insulet (PODD) director awarded 1,660 RSUs in deferred stock grant - Stock Titan
Director at Insulet (NASDAQ: PODD) receives 1,660-share RSU grant - Stock Titan
Insulet (PODD) director granted 1,660 RSUs, total holdings now 3,818 shares - Stock Titan
Insulet (PODD) director Luciana Borio receives 1,660-share RSU equity grant - Stock Titan
Insulet (NASDAQ: PODD) amends bylaws and confirms 2026 shareholder voting outcomes - Stock Titan
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet Corp stock (US45784P1012): William Blair starts coverage as after-hours drop tests investor - AD HOC NEWS
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
PODD Assumed by William Blair -- Rating Action: Outperform - GuruFocus
William Blair initiates Insulet stock coverage with Outperform rating - Investing.com
Insulet Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
A Look At Insulet (PODD) Valuation After A Sharp Share Price Pullback - Yahoo Finance
Insulet Corp stock (US45784P1012): after Q1 beat and raised outlook, investors eye diabetes tech gro - AD HOC NEWS
Insulet Corp (PODD) Shares Surge 3.5% -- What GF Score of 82 Tel - GuruFocus
Insulet Corporation $PODD Stock Holdings Increased by DNB Asset Management AS - MarketBeat
Insulet Corp stock (US45784P1012): diabetes tech player after earnings beat and sharp pullback - AD HOC NEWS
The 5 Most Interesting Analyst Questions From Insulet’s Q1 Earnings Call - Yahoo Finance
Why Insulet (PODD) Stock Is Trading Up Today - Yahoo Finance
Insulet (PODD) CEO McEvoy uses 1,411 shares to cover RSU taxes - Stock Titan
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD) - The Globe and Mail
This Insulet analyst is no longer bullish; here are top 4 downgrades for Friday - MSN
Why Goldman Sachs Trimmed Insulet Corporation (PODD) Price Target Despite Strong Q1 Results - Insider Monkey
Insulet Corp stock (US45784P1012): Hits 52-week low at $148.24 - AD HOC NEWS
Capital Research holds 2.4% of Insulet (NASDAQ: PODD) in Schedule 13G/A - Stock Titan
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
A Look at Insulet Corp (PODD) After 6.0% Decline -- GF Value $38 - GuruFocus
A Look at Insulet Corp (PODD) After 6.0% Decline -- GF Value $385.97 vs Price $148.84 - GuruFocus
Insulet Corporation Stock Watch Rises With Nasdaq Composite Activity - Kalkine Media
Insulet Corporation stock hits 52-week low at 148.24 USD - Investing.com
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings - Yahoo Finance
Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance
Insulet (NASDAQ:PODD) Shares Unloaded Sen. Tina Smith - MarketBeat
Sen. Tina Smith Sells Insulet Corporation (NASDAQ:PODD) Stock - MarketBeat
Benchmark reaffirms Insulet stock rating with $250 price target - Investing.com
Benchmark reaffirms Insulet stock rating with $250 price target By Investing.com - Investing.com UK
Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh - TradingView
Why Insulet (PODD) is a Top Value Stock for the Long-Term - Yahoo Finance
Insulet Corp. Stock Hits Day Low Amid Price Pressure, Drops to $148.45 - Markets Mojo
Mitsubishi UFJ Asset Management Co. Ltd. Purchases 8,172 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corp (PODD) Shares Fall 3.8% -- What GF Score of 83 Tells Investors - GuruFocus
PODD Maintained by JP Morgan -- Price Target Lowered to $275 - GuruFocus
Insulet Corp Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):